Evidence map›Paper›PMID 34547022›Full record

ArticlePloS one2021

Intrapleural use of urokinase and DNase in pleural infections managed with repeated thoracentesis: A comparative cohort study.

David Luque Paz, Betsega Bayeh, Pierre Chauvin, Florence Poizeau, Mathieu Lederlin, Mallorie Kerjouan, Charles Lefevre, Bertrand de Latour, Julien Letheulle, Pierre Tattevin and 1 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Diagnosis and management of pleural infection.Breathe (Sheffield, England) · 2023
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

David Luque PazDepartment of Respiratory Diseases, Rennes University Hospital, Rennes, France.ORCID 0000-0002-9197-7305
Betsega BayehDepartment of Pneumology and Respiratory Functional Exploration, University Hospital of Tours, Tours, France.
Pierre ChauvinDepartment of Respiratory Diseases, Rennes University Hospital, Rennes, France.
Florence PoizeauEA 7449 (Pharmacoepidemiology and Health Services Research) REPERES, Univ Rennes, CHU Rennes, Rennes, France.ORCID 0000-0002-0754-361X
Mathieu LederlinDepartment of Radiology, Pontchaillou University Hospital, Rennes, France.
Mallorie KerjouanDepartment of Respiratory Diseases, Rennes University Hospital, Rennes, France.
Charles LefevreBiochemistry Laboratory, Pontchaillou Hospital CHU Rennes, Rennes, France.
Bertrand de LatourDepartment of Thoracic and Cardiovascular Surgery, Rennes University Hospital, Rennes, France.
Julien LetheulleDepartment of Internal Medicine, Laval Center Hospital, Laval, France.
Pierre TattevinInfectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.
Stéphane JouneauDepartment of Respiratory Diseases, Rennes University Hospital, Rennes, France.
Centre Hospitalier Universitaire de Rennes · FRInserm · FRHôpital Pontchaillou · FRLaboratoire de Biologie Structurale de la Cellule · FRLaval Mayenne Technopole · FRUniversité de Tours · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEvacuation of infected fluid in pleural infections is essential. To date, the use of an intrapleural fibrinolytic agent such as urokinase and DNase has not yet been assessed in infections managed by repeated therapeutic thoracentesis (RTT).

methodsWe performed a retrospective comparative study of two successive cohorts of consecutive patients with pleural infections from 2001 to 2018. Between 2001 and 2010, patients had RTT with intrapleural urokinase (RTT-U). After 2011, patients received intrapleural urokinase and DNase with RTT (RTT-UD). Data were collected through a standardized questionnaire.

resultsOne hundred and thirty-three patients were included: 93 were men and the mean age was 59 years (standard deviation 17.2). Eighty-one patients were treated with a combination of intrapleural urokinase and DNase, and 52 were treated with intrapleural urokinase only. In the RTT-UD, RTT failure occurred in 14 patients (17%) compared to 10 (19%) in the RTT-U group (P = 0.82). There was no difference between the two groups in intensive care unit admission, surgical referrals or in-hospital mortality. RTT-UD was associated with faster time to apyrexia (aOR = 0.51, 95%CI [0.37-0.72]), a reduced length of hospital stay (aOR = 0.61, 95%CI [0.52-0.73]) and a higher volume of total pleural fluid retrieved (aOR = 1.38, 95%CI [1.02-1.88]). Complications were rare with only one hemothorax in the RTT-UD group and no pneumothorax requiring drainage in either group.

conclusionCompared to urokinase only, intrapleural use of urokinase and DNase in RTT was associated with quicker defervescence, shorter hospital stay and increased volumes of pleural fluid drained. Randomized controlled trials evaluating urokinase and DNase with RTT technique would be required to confirm these results.

Indexed as

AdultAgedDeoxyribonucleasesDisease-Free SurvivalDrainageEmpyema, PleuralFemaleHumansMaleMiddle AgedPleuraPleural DiseasesPleural EffusionPneumothoraxRetrospective StudiesSurveys and QuestionnairesDeoxyribonucleasesUrokinase-Type Plasminogen Activator

Identifiers

PMID34547022
PMCPMC8454966
OpenAlexW3200652081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.